Lupin Pharmaceuticals Appoints Claus Jepsen as President of Global Specialty
Prior to his role at Lupin, Jepsen served as the head of Global Strategy for Rare Diseases at Takeda Pharmaceuticals.
Global pharma giant, Lupin Pharmaceuticals has appointed Claus Jepsen as President of Global Specialty.
Jepsen arrives with over 30 years of expertise in commercial strategy, portfolio management, and product launch planning across Europe, Asia, and the United States.
Prior to his role at Lupin, Jepsen served as the head of Global Strategy for Rare Diseases at Takeda Pharmaceuticals.
His previous experience includes significant positions at GlaxoSmithKline, where he acted as country head in Asia and participated in Global Franchise Management for therapeutic areas including Immunology, Respiratory, and Neurology.
Jepsen was instrumental in the US launch of major brands such as Ellipta and contributed to the successful rollout of Advair and Seretide in both European and American markets.
Lupin’s CEO, Vinita Gupta, remarked, “We are delighted to welcome Claus to our executive leadership team. His experience in leading specialty strategy, commercial planning, and portfolio choices across key markets will enable us to build our Specialty brand business.”
Earlier, in June, Lupin appointed Abdelaziz Toumi as the CEO of its newly established subsidiary, Lupin Manufacturing Solutions (LMS).
Lupin’s newly formed subsidiary, Lupin Manufacturing Solutions (LMS), focuses on the development, manufacture, and sale of active pharmaceutical ingredients (API).
Founded in 1968, the Indian multinational pharmaceutical company offers a diverse portfolio of branded and generic formulations, biotechnology products, and APIs.
Lupin serves over 100 markets spanning the US, India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East. Lupin's key focus areas include pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis.
